Patricia Inácio, PhD, science writer —

Scientists have developed a molecule that promotes the clearance of toxic clumps of the alpha-synuclein protein — a hallmark of Parkinson’s disease — by targeting its template rather that the protein itself. “We have found that targeting the RNA needed to build the toxic protein may be an optimal…

The U.S. Food and Drug Administration (FDA) has given Zydus Lifesciences a green light to conduct a Phase 2 trial of ZYIL1, an oral inhibitor of NLRP3 — a protein that’s linked to brain inflammation, or neuroinflammation — in people with Parkinson’s disease. The trial will evaluate the safety…

Neurocrine Biosciences is opening two Phase 1 clinical trials in healthy adults to test two oral candidate muscarinic receptor agonists intended to treat Parkinson’s disease and other neurological conditions. Both investigational therapies — called NBI-1117569 and NBI-1117567 — were developed by Sosei Heptares, which licensed…

Members of the Support Group for Black Patients with Parkinson’s Disease took part in the Parkinson Council’s Walk to Stamp Out Parkinson’s event in November and raised more than $3,400, helping the Council to come within 70% of its $400,000 fundraising goal. The support group, which was launched in…

Two leading nonprofit institutes have launched the GA4GH & INCF Neuroscience Community to better connect researchers around the world studying Parkinson’s disease and other brain disorders, and to improve data sharing globally. The goal of this new network, its creators say, is to tackle the complexity underlying disorders like…

The Institute for Glial Sciences, a center dedicated to the role of glial cells in Parkinson’s disease and others affecting the nervous system with a goal of better treatments, is opening at Case Western Reserve University in Ohio. It will be led by Paul Tesar, PhD, a professor in…

An ongoing and global Phase 3 clinical trial program for oral tavapadon, a selective dopamine receptor agonist aiming to improve motor function in people with Parkinson’s disease, expects to release study findings next year. Three separate, 27-week trials are evaluating tavapadon’s efficacy, safety, and tolerability against…

Enrollment is now complete for a Phase 2 trial that’s assessing the safety and efficacy of oral vodobatinib (K0706), an experimental Abl inhibitor, in people with early Parkinson’s disease across 84 clinical sites in the U.S., Europe, and India. The placebo-controlled trial (NCT03655236), dubbed PROSEEK and sponsored by Sun…

A trial investigating the feasibility and impact of a novel approach for increasing regular exercise among Hispanic people with Parkinson’s disease — the ethnic group in the U.S. with the highest incidence of the neurodegenerative condition — is now recruiting participants. The aim of the new approach is boosting…

ABBV-951 (foslevodopa/foscarbidopa) — Abbvie’s continuous infusion formulation of levodopa/carbidopa that’s administered under the skin — will now be accessible at low or no cost to people in England with advanced Parkinson’s disease whose severe motor fluctuations are no longer controlled by standard treatments. That’s according to the…